- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.07. | Akute Pankreatitis: CalciMedica und FDA einigen sich auf Studiendesign | 4 | Investing.com Deutsch | ||
| 29.07. | CalciMedica, Inc.: CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints | 349 | PR Newswire | FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary... ► Artikel lesen | |
| CALCIMEDICA Aktie jetzt für 0€ handeln | |||||
| 07.07. | CalciMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.06. | FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial | 1 | Benzinga.com | ||
| 24.06. | CalciMedica receives FDA clearance to continue Auxora trial | 1 | Investing.com | ||
| 24.06. | CalciMedica secures up to $49M private placement financing | 1 | Investing.com | ||
| 24.06. | CalciMedica sichert sich bis zu 49 Mio. US-Dollar durch Privatplatzierung | 1 | Investing.com Deutsch | ||
| 24.06. | CalciMedica erhält FDA-Freigabe zur Fortsetzung der Auxora-Studie | - | Investing.com Deutsch | ||
| 24.06. | CalciMedica, Inc.: CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data | 229 | PR Newswire | FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients
No comments or questions were received
Confirms... ► Artikel lesen | |
| 24.06. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | CalciMedica, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | CalciMedica GAAP EPS of -$0.30 | 1 | Seeking Alpha | ||
| 12.05. | CalciMedica, Inc.: CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates | 420 | PR Newswire | FDA feedback on the Auxora pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026
Preclinical and IND-enabling... ► Artikel lesen | |
| 12.05. | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | CalciMedica: NASDAQ bemängelt Börsenwert und Aktienkurs - Delisting droht | 2 | Investing.com Deutsch | ||
| 18.03. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica GAAP EPS of -$1.97 | 1 | Seeking Alpha | ||
| 03.03. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica, Inc.: CalciMedica Reports 2025 Financial Results and Provides Clinical Updates | 876 | PR Newswire | Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,10 | +2,56 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| MODERNA | 49,500 | +5,89 % | Ihre wichtigsten Termine: Spannende Zahlen von: Sony, Moderna, AbbVie, Eaton, ExxonMobil, Linde und Puma! | © Foto: picture alliance / CFOTO | CFOTOGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| AMGEN | 352,70 | +0,36 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,820 | +1,49 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| STRYKER | 292,80 | +0,03 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen | |
| BIOGEN | 179,04 | 0,00 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| ILLUMINA | 164,36 | -2,27 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| CLINUVEL | 5,718 | +1,89 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | +1,21 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,000 | +2,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 43,230 | +8,09 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| EDITAS MEDICINE | 2,570 | +1,58 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,172 | +1,19 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 55,16 | +6,90 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| EXELIXIS | 46,000 | +1,52 % | Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M |
CALCIMEDICA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,08 % bei einem Aktienkurs von 0,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALCIMEDICA INC finden Sie auf Wallstreet Online.